Mayo Clinic and Gilead Sciences Connections

Mayo Clinic has developed a system that utilizes EHR data, non-clinical information, and contact-tracing data to determine which employees have been exposed to the new coronavirus. The tool is able to identify potential coronavirus exposures within an average of two hours after a confirmed Covid-19 case, Mayo said. Mayo plans to roll out the system at its campuses in Arizona and Florida next week, according to Laura Breeher, medical director of Mayo Clinic Occupational Health Services (Drees, Becker's Health IT, 4/14).

https://www.advisory.com/daily-briefing/2020/04/20/covid-roundup

Gilead Sustained Virologic Response (SVR) Registry

This Registry is designed to provide long term clinical and virologic follow up in subjects who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored Hepatitis C Virus (HCV) study. This long term follow up study is observational and no treatment is provided for HCV.

https://www.mayo.edu/research/clinical-trials/cls-20119369

Hennepin Healthcare, Mayo Clinic join trial on potential coronavirus therapy remdesivir

Hennepin Healthcare and Mayo Clinic are participating in an international clinical trial on using the drug remdesivir to treat hospitalized COVID-19 patients.

https://www.twincities.com/2020/04/10/hennepin-healthcare-joins-trial-on-potential-coronavirus-therapy-remdesivir/

Developing an Ethics Framework for Allocating Remdesivir in the COVID-19

Pandemic

https://www.mayoclinicproceedings.org/article/S0025-6196(20)30620-0/pdf